Tom Bumol, Ph.D.
Thomas F. Bumol, Ph.D., is the Executive Director of the Allen Institute for Immunology in Seattle, Washington, a position he assumed on March 1, 2018. He was the Senior Vice-President of the Biotechnology and Immunology Research component at Lilly Research Laboratories, and the Site Head of Lilly’s Biotechnology Center of San Diego, which included the former Applied Molecular Evolution subsidiary of Lilly Research Laboratories and early clinical development for immunology assets from Lilly (phase I and phase II) until his retirement in December of 2017.
A native of Detroit, Michigan, Bumol received his B.S. degree in microbiology with distinction from the University of Michigan in 1975. He subsequently completed his Ph.D. in microbiology-immunology from the University of Minnesota in 1980. Bumol was the recipient of a Damon Runyon-Walter Winchell Cancer Research Fellowship for his postdoctoral studies in the Department of Molecular Immunology at Scripps Clinic and Research Foundation in La Jolla, California from 1980-1982. He joined Lilly Research Laboratories as a Senior Immunologist in 1982 where he remained for his career of over 35 years until his retirement. Bumol has over 50 publications and reviews, 8 issued U.S. patents and his team and collaborators have nominated over 100 molecules into clinical development including dulaglutide (Trulicity), ixekizumab (Taltz), galcanezumab (Emgality) and mirikizumab while at Lilly Research Laboratories. In addition, through strategic alliances his teams helped develop and support ReoPro with Centocor and baricitinib (Olumiant) with Incyte.
He serves on the University of Michigan Technology Transfer National Advisory Board, and Bumol continues to advise Lilly Ventures and several start-up biotechnology companies.